Cargando…

Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma

Anaplastic thyroid carcinoma (ATC) is a deadly disease with very limited therapeutic options. There is an urgent need for new and efficacious drugs. Unfortunately accrual in clinical trials is problematic because of the rarity of the disease and often poor performance status at diagnosis. Recently s...

Descripción completa

Detalles Bibliográficos
Autores principales: Spalart, Valérie, Legius, Barbara, Segers, Kurt, Coolen, Johan, Maes, Brigitte, Decoster, Lynn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899289/
https://www.ncbi.nlm.nih.gov/pubmed/31885948
http://dx.doi.org/10.1155/2019/9095753
_version_ 1783477096675278848
author Spalart, Valérie
Legius, Barbara
Segers, Kurt
Coolen, Johan
Maes, Brigitte
Decoster, Lynn
author_facet Spalart, Valérie
Legius, Barbara
Segers, Kurt
Coolen, Johan
Maes, Brigitte
Decoster, Lynn
author_sort Spalart, Valérie
collection PubMed
description Anaplastic thyroid carcinoma (ATC) is a deadly disease with very limited therapeutic options. There is an urgent need for new and efficacious drugs. Unfortunately accrual in clinical trials is problematic because of the rarity of the disease and often poor performance status at diagnosis. Recently some data have emerged suggesting a role for immunotherapy in the treatment of ATC. We describe the case of a 75-year-old patient with poor performance status and compromised airway and oesophagus at diagnosis, showing a rapid and dramatic response to first line single agent pembrolizumab. Disease progression in the brain occurred 16 months after initial diagnosis. At that time there was ongoing extracranial disease control.
format Online
Article
Text
id pubmed-6899289
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-68992892019-12-29 Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma Spalart, Valérie Legius, Barbara Segers, Kurt Coolen, Johan Maes, Brigitte Decoster, Lynn Case Rep Endocrinol Case Report Anaplastic thyroid carcinoma (ATC) is a deadly disease with very limited therapeutic options. There is an urgent need for new and efficacious drugs. Unfortunately accrual in clinical trials is problematic because of the rarity of the disease and often poor performance status at diagnosis. Recently some data have emerged suggesting a role for immunotherapy in the treatment of ATC. We describe the case of a 75-year-old patient with poor performance status and compromised airway and oesophagus at diagnosis, showing a rapid and dramatic response to first line single agent pembrolizumab. Disease progression in the brain occurred 16 months after initial diagnosis. At that time there was ongoing extracranial disease control. Hindawi 2019-11-26 /pmc/articles/PMC6899289/ /pubmed/31885948 http://dx.doi.org/10.1155/2019/9095753 Text en Copyright © 2019 Valérie Spalart et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Spalart, Valérie
Legius, Barbara
Segers, Kurt
Coolen, Johan
Maes, Brigitte
Decoster, Lynn
Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma
title Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma
title_full Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma
title_fullStr Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma
title_full_unstemmed Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma
title_short Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma
title_sort dramatic response to first line single agent pembrolizumab in anaplastic thyroid carcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899289/
https://www.ncbi.nlm.nih.gov/pubmed/31885948
http://dx.doi.org/10.1155/2019/9095753
work_keys_str_mv AT spalartvalerie dramaticresponsetofirstlinesingleagentpembrolizumabinanaplasticthyroidcarcinoma
AT legiusbarbara dramaticresponsetofirstlinesingleagentpembrolizumabinanaplasticthyroidcarcinoma
AT segerskurt dramaticresponsetofirstlinesingleagentpembrolizumabinanaplasticthyroidcarcinoma
AT coolenjohan dramaticresponsetofirstlinesingleagentpembrolizumabinanaplasticthyroidcarcinoma
AT maesbrigitte dramaticresponsetofirstlinesingleagentpembrolizumabinanaplasticthyroidcarcinoma
AT decosterlynn dramaticresponsetofirstlinesingleagentpembrolizumabinanaplasticthyroidcarcinoma